Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis

被引：20

作者：

Raina, Rupesh ^{[1
,4
]}

Wang, Joseph ^{[2
]}

Sharma, Aditya ^{[3
]}

Chakraborty, Ronith ^{[4
]}

机构：

[1] Akron Childrens Hosp, Dept Pediat Nephrol, Akron, OH 44308 USA

[2] Univ Nebraska Med Ctr, Dept Internal Med & Pediat, Omaha, NE USA

[3] Northeast Ohio Med Univ, Rootstown, OH USA

[4] Cleveland Clin Akron Gen, Akron Nephrol Associates, Akron, OH USA

来源：

BLOOD PURIFICATION | 2020年 / 49卷 / 05期

关键词：

Focal segmental glomerulosclerosis; Extracorporeal therapy; Low-density lipoprotein apheresis; Plasma exchange; Immunoadsorption;

D O I：

10.1159/000506277

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Focal segmental glomerulosclerosis (FSGS) is one of the most frequent and severe glomerular kidney disease with frequent progression to end-stage renal disease and a high rate of recurrence in renal transplantations. Due to intolerance or resistance to the current immunomodulatory treatments, the management of FSGS is a therapeutic challenge. Over the last few years, development in extracorporeal therapies has shown potential beneficial outcomes in drug-resistant and recurrent FSGS patients. Thus, this study reviews the current literature on the use of extracorporeal therapies, such as plasma exchange therapy, immunoadsorption, and low-density lipoprotein apheresis, for the treatment of FSGS in the pediatric population. (C) 2020 S. Karger AG, Basel

引用

页码：513 / 523

页数：11